QuickVue SARS Antigen FIA Dipstick

SKU
QDL-20387
$200.00

(25 Tests per Kit)

NOW IN STOCK SHIPS IMMEDIATELY

REDUCED PRICE AND TIER PRICING!

FREE Next Day Air Shipping Available for Orders of 6 or More Kits!

New Tiered Pricing Quantity Required Price per Kit
Tier 1 1 - 5 Kits $200 per Kit
Tier 2 6 - 39 Kits $187.50 per Kit
Tier 3 40 Kits $175 per Kit
     

 

QuickVue SARS Antigen FIA Dipstick, Nasal Swab.

The QuickVue SARS Antigen Test is a lateral flow immunoassay that allows for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nares (NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms.

The QuickVue SARS Antigen test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings. The QuickVue SARS Antigen test is only for use under the Food and Drug Administration’s Emergency Use Authorization.

  • For use under the Emergency Use Authorization (EUA) only
  • For in vitro diagnostic use
  • Rx Only

REFUND POLICY for COVID-19 Test: The standard CLIAwaived refund policy does not apply for COVID-19 rapid tests. All sales are final once goods are shipped and in transit with courier. NO EXCHANGES OR REFUNDS WILL BE MADE.

* REQUIRED FIELDS IN ORDER TO PURCHASE

All clinical specimens must be at room temperature before beginning the assay.

Performing the assay outside the time and temperature ranges provided may produce invalid results.

Assays not performed within the established time and temperature ranges must be repeated.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The QuickVue SARS Antigen test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nares specimens during the acute phase of infection.

© 2020 Cliawaived, Inc. All Rights Reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.